3 Dow Movers Ending the Week on Trader Radars

Drug manufacturer Mylan (NASDAQ:MYL) is set to release Atorvastatin Calcium Tablets in Belgium, France, Ireland, the Netherlands, and the United Kingdom. The drug, which is a generic of Pfizer Inc.’s (NYSE:PFE) best-selling cholesterol pharmaceutical Lipitor, will be available in 10 mg, 20 mg, 40 mg, and 80 mg increments. With approval from each country’s respective health authority secured, Atorvastatin Calcium will be on the market immediately. Shares of Pfizer recently traded at $22.85, up $0.02, or 0.09%.

Don’t Miss: Are These Big Shareholders Scaling Back Their JPMorgan Holdings?

Can you hear T-Mobile now? Apparently not. According to The Wall Street Journal, T-Mobile USA (DTEGY) lost over 500,000 of their most lucrative customers during the first three months of the year. This steep decline may indicate that the mobile carrier has lost its momentum after its sale to AT&T, Inc. (NYSE:T) was blocked by the Justice Department last year. AT&T CEO Randall Stephenson asked that the federal government figure out how to trim some of the regulatory red tape that is impeding wireless growth and forcing companies to increase prices, reported Bloomberg. T-Mobile shares recently traded at $33.86, up $0.73.

Verizon Communications Inc. (NYSE:VZ) signal is about to get a lot clearer. The telecommunications company will reportedly build additional control plane technology into its network infrastructure. This upgrade will enable electronic devices on its optical network to communicate more easily with each other.  As a result, operations will be simplified and will allow for near real-time provisioning of specified new circuits. Verizon shares recently traded at $41.37, up $0.82, or 2.02%.

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.

Don’t Miss: Intel to Apple: We Will Not Be Ignored!